Convey Holding Parent (NYSE:CNVY) vs. Baudax Bio (NASDAQ:BXRX) Critical Comparison

Convey Holding Parent (NYSE:CNVY) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Earnings & Valuation

This table compares Convey Holding Parent and Baudax Bio’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Convey Holding Parent $282.91 million 2.02 N/A N/A N/A
Baudax Bio $490,000.00 104.38 -$76.10 million ($2.31) -0.26

Convey Holding Parent has higher revenue and earnings than Baudax Bio.


This table compares Convey Holding Parent and Baudax Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Convey Holding Parent N/A N/A N/A
Baudax Bio -6,924.13% N/A -82.58%

Analyst Ratings

This is a breakdown of recent ratings for Convey Holding Parent and Baudax Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Convey Holding Parent 0 1 7 0 2.88
Baudax Bio 0 0 0 0 N/A

Convey Holding Parent currently has a consensus price target of $14.86, suggesting a potential upside of 89.54%. Given Convey Holding Parent’s higher possible upside, analysts plainly believe Convey Holding Parent is more favorable than Baudax Bio.

Institutional and Insider Ownership

92.2% of Convey Holding Parent shares are held by institutional investors. Comparatively, 8.7% of Baudax Bio shares are held by institutional investors. 2.6% of Baudax Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Convey Holding Parent beats Baudax Bio on 6 of the 8 factors compared between the two stocks.

About Convey Holding Parent

Convey Holding Parent, Inc., together with its subsidiaries, provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics in the United States. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company's software solutions for health plans include enrollment and billing technology, supplemental benefits solution, agent and broker management, membership and financial reconciliation, compliance monitoring, and data analytic solutions. The Advisory Services segment offers advisory services, including sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. The company serves government sponsored, medicare, medicaid, and provided sponsored plans, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Holding Parent, Inc. is a subsidiary of TPG Cannes Aggregation, L.P.

About Baudax Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Receive News & Ratings for Convey Holding Parent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Convey Holding Parent and related companies with's FREE daily email newsletter.